Literature DB >> 22213739

Rapid molecular detection of tuberculosis and rifampicin drug resistance: retrospective analysis of a national U.K. molecular service over the last decade.

N Seoudi1, S L Mitchell, T J Brown, F Dashti, A K Amin, F A Drobniewski.   

Abstract

BACKGROUND: Fast and reliable detection of Mycobacterium tuberculosis complex (MTBC) and drug resistance is crucial in establishing effective treatment and enforcing timely public health measures.
METHODS: The authors analysed the performance of a national U.K. molecular diagnostic service over a decade, based on the use of a line probe assay (Innolipa, LiPA) compared with conventional liquid and solid cultures with rapid molecular identification and culture-based drug resistance testing.
FINDINGS: Data were available for 7836 consecutive patient samples using LiPA and the reference microbiological technique (conventional liquid and solid cultures with rapid molecular identification and culture-based drug resistance testing). For all sputum specimens (n=3382) the sensitivity, specificity, positive predictive value, negative predictive value and accuracy for MTBC detection were 93.4%, 85.6%, 92.7%, 86.9% and 90.7%; the equivalent values for smear-positive sputum specimens (n=2606) were 94.7%, 80.9%, 93.9%, 83.3% and 91.3%. The sensitivity, specificity, positive predictive value, negative predictive value and accuracy for detection of rifampicin resistance in all sputum samples (n=1667) were 92.1%, 99.3%, 89.4%, 99.5% and 98.9%, respectively; the equivalent values for smear-positive sputum specimens (n=1477) were 93.3%, 99.3%, 87.5%, 99.6% and 99%. Between January 2006 and December 2008, LiPA saved 25.3 and 32.2 days for TB diagnosis and rifampicin resistance of smear-positive samples, respectively.
INTERPRETATION: A molecular diagnostic service, using a non-automated line probe assay approach, provides a rapid and reliable national service for diagnosing MTBC and rifampicin resistance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22213739     DOI: 10.1136/thoraxjnl-2011-200610

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  5 in total

1.  Rapid implementation of new TB diagnostic tests: is it too soon for a global roll-out of Xpert MTB/RIF?

Authors:  Daniela E Kirwan; María Kathia Cárdenas; Robert H Gilman
Journal:  Am J Trop Med Hyg       Date:  2012-08       Impact factor: 2.345

2.  Edge map analysis in chest X-rays for automatic pulmonary abnormality screening.

Authors:  K C Santosh; Szilárd Vajda; Sameer Antani; George R Thoma
Journal:  Int J Comput Assist Radiol Surg       Date:  2016-03-19       Impact factor: 2.924

3.  Evaluation of rapid diagnostic tests and assessment of risk factors in drug-resistant pulmonary tuberculosis.

Authors:  Vimal Kumar; Pankaj Jorwal; Manish Soneja; Sanjeev Sinha; Neeraj Nischal; Prayas Sethi; Saikat Mondal; Zia Abdullah; R M Pandey
Journal:  J Family Med Prim Care       Date:  2020-02-28

4.  Multidrug and extensively drug-resistant tuberculosis in Canada 1997-2008: demographic and disease characteristics.

Authors:  Jessica Minion; Victor Gallant; Joyce Wolfe; Frances Jamieson; Richard Long
Journal:  PLoS One       Date:  2013-01-09       Impact factor: 3.240

Review 5.  Rapid diagnostics of tuberculosis and drug resistance in the industrialized world: clinical and public health benefits and barriers to implementation.

Authors:  Francis Drobniewski; Vladyslav Nikolayevskyy; Horst Maxeiner; Yanina Balabanova; Nicola Casali; Irina Kontsevaya; Olga Ignatyeva
Journal:  BMC Med       Date:  2013-08-29       Impact factor: 8.775

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.